Log In Sign up
The largest database of trusted experimental protocols

Phospho egfr y1068

Manufactured by Abcam
Visit Supplier

Phospho-EGFR Y1068 is a monoclonal antibody that detects the phosphorylation of the epidermal growth factor receptor (EGFR) at tyrosine residue 1068. This antibody can be used in various immunoassays to measure the levels of phosphorylated EGFR at this specific site.

Automatically generated - may contain errors

Lab products found in correlation

Akt1 2 3, by Santa Cruz Biotechnology (4 mentions) Wz4002, by Selleck Chemicals (4 mentions) Nvp aew541, by Selleck Chemicals (2 mentions) Perk1 2 t202 204, by Cell Signaling Technology (2 mentions) Abt 263, by Selleck Chemicals (2 mentions) Pakt s473, by Cell Signaling Technology (2 mentions) Phospho egfr y1068, by Cell Signaling Technology (2 mentions) Bgj398, by Selleck Chemicals (2 mentions) Gefitinib, by Selleck Chemicals (2 mentions) Phospho akt s473, by Cell Signaling Technology (2 mentions) Azd9291, by Selleck Chemicals (2 mentions) Fgfr1, by Cell Signaling Technology (2 mentions) Phospho erk1 2t202 y204, by Cell Signaling Technology (2 mentions) Fgfr3, by Cell Signaling Technology (2 mentions) Phospho frs2αy436, by Cell Signaling Technology (2 mentions) N cadherin, by Cell Signaling Technology (2 mentions) E cadherin, by Cell Signaling Technology (2 mentions) Vimentin, by Cell Signaling Technology (2 mentions) Erk1 2, by Cell Signaling Technology (2 mentions) Bradford dye reagent, by Bio-Rad (1 mentions)

5 protocols using phospho egfr y1068

1

Western Blotting with Targeted Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols
For western blotting, the following antibodies were used: phospho-EGFR Y1068 (Abcam); EGFR, pERK1/2 T202/204, ERK1/2, p-AKT S473, BIM, Actin (Cell Signaling); AKT1/2/3 (Santa Cruz). For cell culture studies, gefitinib, WZ4002, NVP-AEW541, ABT-263 (all from Selleck), were dissolved in DMSO to a final concentration of 10 mmol/l and stored at −20°C. Unless otherwise specified, 1 μM concentration was used for in vitro cell culture experiments.
Hata A.N., Niederst M.J., Archibald H.L., Gomez-Caraballo M., Siddiqui F.M., Mulvey H.E., Maruvka Y.E., Ji F., Bhang H.E., Radhakrishna V.K., Siravegna G., Hu H., Raoof S., Lockerman E., Kalsy A., Lee D., Keating C.L., Ruddy D.A., Damon L.J., Crystal A.S., Costa C., Piotrowska Z., Bardelli A., Iafrate A.J., Sadreyev R.I., Stegmeier F., Getz G., Sequist L.V., Faber A.C, & Engelman J.A. (2016). Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nature medicine, 22(3), 262-269.
+ Open protocol
+ Expand
2

Investigating EGFR and FGF Signaling Pathways

Check if the same lab product or an alternative is used in the 5 most similar protocols
The following antibodies were used: phospho EGFR Y1068 (Abcam AB5644),
phospho EGFR Y1068 (Cell Signaling 3777), EGFR (Cell Signaling 2646), EGFR (Cell
Signaling 4267), phospho ERK1/2 T202/Y204 (Cell Signaling 9101), phospho ERK1/2,
T202/Y204 (Cell Signaling 4370), ERK1/2 (Cell Signaling 9102), phospho AKT S473
(Cell Signaling 4060), AKT1/2/3 (Santa Cruz sc-8312), BIM (Cell Signaling 2933),
Actin (Cell Signaling 4970), Actin-HRP conjugated (Cell Signaling 12262), FGFR1
(Cell Signaling 9740), and FGFR3 (Cell Signaling 4574), phospho FRS2α
Y436 (Cell Signaling 3861), E-Cadherin (Cell Signaling 3195), N-Cadherin (Cell
Signaling 13116), Zeb1 (Cell Signaling 3396), Vimentin (Cell Signaling 5741).
Gefitinib, WZ4002, AZD9291, and BGJ398 (all from Selleck) were dissolved in DMSO
to a final concentration of 10 mmol/liter and stored at −20 °C.
The 18 drugs tested in the long-term assay are listed in Supplemental Table 3.
Raoof S., Mulford I.J., Frisco-Cabanos H., Nangia V., Timonina D., Labrot E., Hafeez N., Bilton S.J., Drier Y., Ji F., Greenberg M., Williams A., Kattermann K., Damon L., Sovath S., Rakiec D.P., Korn J.M., Ruddy D.A., Benes C.H., Hammerman P.S., Piotrowska Z., Sequist L.V., Niederst M.J., Barretina J., Engelman J.A, & Hata A.N. (2019). Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer. Oncogene, 38(37), 6399-6413.
+ Open protocol
+ Expand
3

Western Blotting with Targeted Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols
For western blotting, the following antibodies were used: phospho-EGFR Y1068 (Abcam); EGFR, pERK1/2 T202/204, ERK1/2, p-AKT S473, BIM, Actin (Cell Signaling); AKT1/2/3 (Santa Cruz). For cell culture studies, gefitinib, WZ4002, NVP-AEW541, ABT-263 (all from Selleck), were dissolved in DMSO to a final concentration of 10 mmol/l and stored at −20°C. Unless otherwise specified, 1 μM concentration was used for in vitro cell culture experiments.
Hata A.N., Niederst M.J., Archibald H.L., Gomez-Caraballo M., Siddiqui F.M., Mulvey H.E., Maruvka Y.E., Ji F., Bhang H.E., Radhakrishna V.K., Siravegna G., Hu H., Raoof S., Lockerman E., Kalsy A., Lee D., Keating C.L., Ruddy D.A., Damon L.J., Crystal A.S., Costa C., Piotrowska Z., Bardelli A., Iafrate A.J., Sadreyev R.I., Stegmeier F., Getz G., Sequist L.V., Faber A.C, & Engelman J.A. (2016). Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nature medicine, 22(3), 262-269.
+ Open protocol
+ Expand
4

Investigating EGFR and FGF Signaling Pathways

Check if the same lab product or an alternative is used in the 5 most similar protocols
The following antibodies were used: phospho EGFR Y1068 (Abcam AB5644),
phospho EGFR Y1068 (Cell Signaling 3777), EGFR (Cell Signaling 2646), EGFR (Cell
Signaling 4267), phospho ERK1/2 T202/Y204 (Cell Signaling 9101), phospho ERK1/2,
T202/Y204 (Cell Signaling 4370), ERK1/2 (Cell Signaling 9102), phospho AKT S473
(Cell Signaling 4060), AKT1/2/3 (Santa Cruz sc-8312), BIM (Cell Signaling 2933),
Actin (Cell Signaling 4970), Actin-HRP conjugated (Cell Signaling 12262), FGFR1
(Cell Signaling 9740), and FGFR3 (Cell Signaling 4574), phospho FRS2α
Y436 (Cell Signaling 3861), E-Cadherin (Cell Signaling 3195), N-Cadherin (Cell
Signaling 13116), Zeb1 (Cell Signaling 3396), Vimentin (Cell Signaling 5741).
Gefitinib, WZ4002, AZD9291, and BGJ398 (all from Selleck) were dissolved in DMSO
to a final concentration of 10 mmol/liter and stored at −20 °C.
The 18 drugs tested in the long-term assay are listed in Supplemental Table 3.
Raoof S., Mulford I.J., Frisco-Cabanos H., Nangia V., Timonina D., Labrot E., Hafeez N., Bilton S.J., Drier Y., Ji F., Greenberg M., Williams A., Kattermann K., Damon L., Sovath S., Rakiec D.P., Korn J.M., Ruddy D.A., Benes C.H., Hammerman P.S., Piotrowska Z., Sequist L.V., Niederst M.J., Barretina J., Engelman J.A, & Hata A.N. (2019). Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer. Oncogene, 38(37), 6399-6413.
+ Open protocol
+ Expand
5

Comprehensive Western Blot Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cells were washed with ice-cold PBS and lysed with RIPA buffer (Cell Signaling Technology) supplemented with protease and phosphatase inhibitors (Roche). Protein levels were quantified with Bradford dye reagent (Bio-Rad), and equal amounts were loaded for SDS/PAGE using precast Bis-Tris gels (Invitrogen), followed by transfer to polyvinylidene difluoride membranes. Membranes were blotted with the following antibodies according to the supplier’s recommendations and were all obtained from Cell Signaling Technology unless otherwise noted: phospho-EGFR Y1068 (no. 3777), EGFR E746-A750del specific (no. 2085), phospo-MET Y1234/1235 (no. 3777), MET (no. 8198), phospho-SFK (no. 6943), YES (no. 3201), phospho-YAP1 Y357 (no. ab62751; Abcam), YAP1 (no. 14704), phospho-AKT S473 (no. 4060), AKT (no. 4691), phospho-ERK T202/Y204 (no. 4370), ERK (no. 4695), phospho-ERBB3 Y1197 (no. 4561), ERBB3 (no. 12708), and GAPDH (no. 2118). Human phosphokinase (no. ARY003B; R&D Systems) and human phospho-RTK (no. ARY001B; R&D Systems) array kits were used according to the manufacturer’s protocols.
Fan P.D., Narzisi G., Jayaprakash A.D., Venturini E., Robine N., Smibert P., Germer S., Yu H.A., Jordan E.J., Paik P.K., Janjigian Y.Y., Chaft J.E., Wang L., Jungbluth A.A., Middha S., Spraggon L., Qiao H., Lovly C.M., Kris M.G., Riely G.J., Politi K., Varmus H, & Ladanyi M. (2018). YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. Proceedings of the National Academy of Sciences of the United States of America, 115(26), E6030-E6038.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!